FY2025 Earnings Estimate for ITCI Issued By Leerink Partnrs

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) – Equities research analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for Intra-Cellular Therapies in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $0.50 for the year, down from their prior estimate of $0.55. The consensus estimate for Intra-Cellular Therapies’ current full-year earnings is ($0.59) per share.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company had revenue of $161.40 million for the quarter, compared to analysts’ expectations of $157.74 million. During the same quarter last year, the business earned ($0.45) earnings per share. Intra-Cellular Therapies’s revenue was up 45.7% on a year-over-year basis.

A number of other research analysts have also recently issued reports on ITCI. JPMorgan Chase & Co. lifted their target price on Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. The Goldman Sachs Group decreased their target price on Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Royal Bank of Canada lifted their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Mizuho lifted their target price on Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, June 21st. Finally, UBS Group decreased their target price on Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.62.

Intra-Cellular Therapies Stock Down 0.4 %

Intra-Cellular Therapies stock opened at $78.34 on Thursday. Intra-Cellular Therapies has a 12-month low of $45.50 and a 12-month high of $84.89. The business’s 50-day moving average price is $74.43 and its two-hundred day moving average price is $72.45. The stock has a market cap of $8.27 billion, a PE ratio of -67.53 and a beta of 1.00.

Insider Buying and Selling

In related news, EVP Mark Neumann sold 18,714 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Intra-Cellular Therapies news, EVP Mark Neumann sold 18,714 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sharon Mates sold 34,396 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $77,962,764.36. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 175,316 shares of company stock valued at $13,037,345 over the last ninety days. 3.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently modified their holdings of ITCI. Perceptive Advisors LLC boosted its holdings in shares of Intra-Cellular Therapies by 62.6% during the 2nd quarter. Perceptive Advisors LLC now owns 1,716,407 shares of the biopharmaceutical company’s stock worth $117,557,000 after buying an additional 661,052 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Intra-Cellular Therapies by 214.5% in the 2nd quarter. Millennium Management LLC now owns 889,102 shares of the biopharmaceutical company’s stock worth $60,895,000 after purchasing an additional 606,358 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Intra-Cellular Therapies by 6.5% in the 4th quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock worth $651,334,000 after purchasing an additional 554,577 shares in the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Intra-Cellular Therapies by 21.2% in the 2nd quarter. Avoro Capital Advisors LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $205,470,000 after purchasing an additional 525,000 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Intra-Cellular Therapies in the 2nd quarter worth $34,178,000. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.